Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25.
Radar 75 (high attention) · dilution pressure elevated · listing risk elevated · governance risk elevated · runway 10.0 mo · strongest signal: Minimum bid deficiency (Aug 3, 2026)
What would confirm: Nasdaq 'Pending Suspension' listing, Form 25, hearings-panel denial 8-K, or a reverse-split proxy.
What would prove it wrong: 8-K announcing regained compliance; equity raise that restores stockholders' equity; MVLS back above threshold for 10+ days.
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 138 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 10, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-10 (accepted 14:17 ET) filing | 41 |
| Aug 10, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-10.1) filed 2026-08-10 filing | 38 |
| Aug 3, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (EX-99.1) filed 2026-08-03 filing | 42 |
| Aug 3, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-99.1) filed 2026-08-03 filing | 37 |
| Aug 3, 2026 | ▼ Holder rights modified | 8-K Item 3.03 filed 2026-08-03 (accepted 13:26 ET) filing | 28 |
| Jul 17, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-07-17 filing | 32 |
| Jul 17, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-07-17 (accepted 16:37 ET) filing | 27 |
| Mar 31, 2026 | ▼ Runway 6–12 months | ~10.0 months runway: liquidity $5,750,000 as of 2026-03-31, burn $6,917,000/yr (latest fiscal-year operating cash flow (quarter too short to annualize) [companyfacts]) filing | 21 |
VIVS VivoSim Labs, INC. · DAIC CID Holdco, Inc. · NCRA NOCERA, INC. · GNPX Genprex, Inc. · FLD Fold Holdings, Inc. · HCWB HCW Biologics Inc. · screener →